Edited by Philip Debruyne.
Citation: BMC Medical Research Methodology 2016 16(Suppl 1):74
Volume 16 Supplement 1
Publication of this supplement was supported by Amgen, Bayer Pharms AG and Hoffman La Roche. Articles have undergone the journal's standard peer review process for supplements. The Supplement Editor declares that they have no competing interests.
Edited by Philip Debruyne.
Citation: BMC Medical Research Methodology 2016 16(Suppl 1):74
Greater transparency and, in particular, sharing of patient-level data for further scientific research is an increasingly important topic for the pharmaceutical industry and other organisations who sponsor and...
Citation: BMC Medical Research Methodology 2016 16(Suppl 1):77
Greater transparency, including sharing of patient-level data for further research, is an increasingly important topic for organisations who sponsor, fund and conduct clinical trials. This is a major paradigm ...
Citation: BMC Medical Research Methodology 2016 16(Suppl 1):76
Access to patient level datasets from clinical trial sponsors continues to be an important topic for the Pharmaceutical Industry as well as academic institutions and researchers. How to make access to patient ...
Citation: BMC Medical Research Methodology 2016 16(Suppl 1):73
Greater transparency and, in particular, sharing of clinical study reports and patient level data for further research is an increasingly important topic for the pharmaceutical and biotechnology industry and o...
Citation: BMC Medical Research Methodology 2016 16(Suppl 1):75
Speed
79 days to first decision for reviewed manuscripts only
58 days to first decision for all manuscripts
196 days from submission to acceptance
19 days from acceptance to publication
Citation Impact
3.031 - 2-year Impact Factor
4.837 - 5-year Impact Factor
1.741 - Source Normalized Impact per Paper (SNIP)
1.614 - SCImago Journal Rank (SJR)
Usage
3,218,958 Downloads
3,897 Altmetric mentions